Fact based stock research
Humana (NYSE:HUM)


Humana stock research in summary

humana.com


Humana shares have a BUY rating. They are safely financed and show above average growth, but are bad value. We recommend buying and holding Humana shares.


Latest Obermatt Ranks


Country USA
Industry Managed Health Care
Index S&P 500, D.J. US Health Care
Size class XX-Large

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()




Research History: Humana

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
18
8
17
9
STOCK GROWTH RANKS
77
32
62
78
STOCK SAFETY RANKS
77
89
100
96
COMBINED STOCK RANKS
64
32
42
83

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Humana in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Humana; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
65
25
18
18
PROFIT GROWTH
66
42
42
89
STOCK RETURNS
86
56
64
84
CONSOLIDATED RANK: GROWTH
77
32
62
78

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Humana.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
66
72
92
92
REFINANCING
68
70
52
48
LIQUIDITY
63
80
72
96
CONSOLIDATED RANK: SAFETY
77
89
100
96

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Humana and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Humana from June 8, 2018.